Limits...
Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia.

Ye D, Garcia-Manero G, Kantarjian HM, Xiao L, Vadhan-Raj S, Fernandez MH, Nguyen MH, Medeiros LJ, Bueso-Ramos CE - J Hematop (2008)

Bottom Line: Aurora A mRNA levels correlated with total and phosphorylated protein levels (P = 0.0002 and P = 0.02, respectively).No significant correlation was found between aurora A mRNA level and blast count, blast viability, cytogenetic abnormalities, or the International Prognostic Scoring System score in patients with myelodysplastic syndromes.We conclude that aurora A is up-regulated in CD34(+) blasts from myeloid neoplasms.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA.

ABSTRACT
Aurora kinase A, also known as aurora A, is a serine/threonine kinase that plays critical roles in mitosis entry, chromosome alignment, segregation, and cytokinesis. Overexpression of aurora A has been observed in many solid tumors and some hematopoietic neoplasms, but little is known about its expression in myeloid diseases. Because cytogenetic abnormalities play an essential role in the pathogenesis of myeloid malignancies, we hypothesized that aurora A deregulation may be involved in myelodysplastic syndromes and acute myeloid leukemia and contribute to the chromosomal instability observed in these diseases. We assessed aurora A mRNA levels in CD34(+) bone marrow blasts from nine patients with acute myeloid leukemia, 20 patients with myelodysplastic syndromes, and five normal patients serving as controls. CD34(+) blasts were isolated from bone marrow aspirate specimens using magnetic activated cell separation technology. RNA was extracted from purified CD34(+) cells, and quantitative real-time reverse transcriptase polymerase chain reaction for aurora A was performed. Immunocytochemical analyses for total aurora A, phosphorylated aurora A, Ki-67, and activated caspase 3 were performed on cytospin slides made from purified CD34(+) cells in myelodysplastic syndrome patients using standard methods. Aurora A mRNA and protein levels were correlated, as was aurora A mRNA level, with blast counts, cytogenetic abnormalities, and International Prognostic Scoring System score. We found that CD34(+) cells in myelodysplastic syndromes and acute myeloid leukemia expressed aurora A at significantly higher levels (P = 0.01 and P = 0.01, respectively) than normal CD34(+) cells. Aurora A mRNA levels correlated with total and phosphorylated protein levels (P = 0.0002 and P = 0.02, respectively). No significant correlation was found between aurora A mRNA level and blast count, blast viability, cytogenetic abnormalities, or the International Prognostic Scoring System score in patients with myelodysplastic syndromes. We conclude that aurora A is up-regulated in CD34(+) blasts from myeloid neoplasms.

No MeSH data available.


Related in: MedlinePlus

AA mRNA levels in both AML and MDS patients
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2713495&req=5

Fig1: AA mRNA levels in both AML and MDS patients

Mentions: Use of RT-PCR revealed that, in five control patients, AA mRNA levels ranged from 0.17 to 0.55. In MDS patients, the median AA mRNA level was 0.99 (range, 0.2 to 2.17). In AML patients, the median AA mRNA level was 0.76 (range, 0.19 to 2.31). Compared with controls, AA mRNA levels were significantly higher in both AML (P = 0.01) and MDS patients (P = 0.01; Fig. 1). There was no significant difference in AA mRNA levels between AML and MDS patients.Fig. 1


Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia.

Ye D, Garcia-Manero G, Kantarjian HM, Xiao L, Vadhan-Raj S, Fernandez MH, Nguyen MH, Medeiros LJ, Bueso-Ramos CE - J Hematop (2008)

AA mRNA levels in both AML and MDS patients
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2713495&req=5

Fig1: AA mRNA levels in both AML and MDS patients
Mentions: Use of RT-PCR revealed that, in five control patients, AA mRNA levels ranged from 0.17 to 0.55. In MDS patients, the median AA mRNA level was 0.99 (range, 0.2 to 2.17). In AML patients, the median AA mRNA level was 0.76 (range, 0.19 to 2.31). Compared with controls, AA mRNA levels were significantly higher in both AML (P = 0.01) and MDS patients (P = 0.01; Fig. 1). There was no significant difference in AA mRNA levels between AML and MDS patients.Fig. 1

Bottom Line: Aurora A mRNA levels correlated with total and phosphorylated protein levels (P = 0.0002 and P = 0.02, respectively).No significant correlation was found between aurora A mRNA level and blast count, blast viability, cytogenetic abnormalities, or the International Prognostic Scoring System score in patients with myelodysplastic syndromes.We conclude that aurora A is up-regulated in CD34(+) blasts from myeloid neoplasms.

View Article: PubMed Central - PubMed

Affiliation: Department of Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA.

ABSTRACT
Aurora kinase A, also known as aurora A, is a serine/threonine kinase that plays critical roles in mitosis entry, chromosome alignment, segregation, and cytokinesis. Overexpression of aurora A has been observed in many solid tumors and some hematopoietic neoplasms, but little is known about its expression in myeloid diseases. Because cytogenetic abnormalities play an essential role in the pathogenesis of myeloid malignancies, we hypothesized that aurora A deregulation may be involved in myelodysplastic syndromes and acute myeloid leukemia and contribute to the chromosomal instability observed in these diseases. We assessed aurora A mRNA levels in CD34(+) bone marrow blasts from nine patients with acute myeloid leukemia, 20 patients with myelodysplastic syndromes, and five normal patients serving as controls. CD34(+) blasts were isolated from bone marrow aspirate specimens using magnetic activated cell separation technology. RNA was extracted from purified CD34(+) cells, and quantitative real-time reverse transcriptase polymerase chain reaction for aurora A was performed. Immunocytochemical analyses for total aurora A, phosphorylated aurora A, Ki-67, and activated caspase 3 were performed on cytospin slides made from purified CD34(+) cells in myelodysplastic syndrome patients using standard methods. Aurora A mRNA and protein levels were correlated, as was aurora A mRNA level, with blast counts, cytogenetic abnormalities, and International Prognostic Scoring System score. We found that CD34(+) cells in myelodysplastic syndromes and acute myeloid leukemia expressed aurora A at significantly higher levels (P = 0.01 and P = 0.01, respectively) than normal CD34(+) cells. Aurora A mRNA levels correlated with total and phosphorylated protein levels (P = 0.0002 and P = 0.02, respectively). No significant correlation was found between aurora A mRNA level and blast count, blast viability, cytogenetic abnormalities, or the International Prognostic Scoring System score in patients with myelodysplastic syndromes. We conclude that aurora A is up-regulated in CD34(+) blasts from myeloid neoplasms.

No MeSH data available.


Related in: MedlinePlus